Results 111 to 120 of about 80,628 (293)

Correlation Between Different Salivary Interleukins and Clinical Periodontal Parameters

Medical Journal of Babylon
Background: Periodontitis is a multifactorial disease that affects tooth-supporting structures which consequently lead to loss of tooth support and tooth loss. Interleukins showed an important role in periodontal destruction.
Sura Dakhil Jassim, Zainab Hadi Kamil, Zeyad Nazar Majeed   +2 more
doaj   +1 more source

Associations of Lifestyle‐Related Factors and Psoriatic Arthritis Disease Activity: The Dutch South West Psoriatic Arthritis Study

Arthritis Care &Research, EarlyView.
Objective This study aims to investigate lifestyle‐related factors in patients with psoriatic arthritis (PsA) and their association with disease activity measurements. Methods This multicenter cohort included 938 patients who were newly diagnosed with PsA between 2013 and 2023.
Batoul Hojeij, Ilja Tchetverikov, Marc R. Kok, Marijn Vis, Yvonne Goekoop‐Ruiterman, Jessica Bijsterbosch, Paul Baudoin, Reinhard Bos, Jos H. van der Kaap, Petra Kok, Lindy‐Anne Korswagen, Jolanda J. Luime   +11 more
wiley   +1 more source

New Possibilities for the Treatment of Crohn’s Disease

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2019
Aim. To review data on the efficiency and safety of using Ustekinumab in patients with Crohn’s disease.Key findings. Ustekinumab is a fully human monoclonal antibody of the IgG1k class to the p40 subunit of IL-12 and IL-23.
Z. A. Mamieva, E. A. Poluektova, O. S. Shifrin   +2 more
doaj   +1 more source

Receptors for interleukin 4, interleukin 5 and interleukin 6.

Annali dell'Istituto superiore di sanita, 1991
cDNA encoding IL-4, IL-5 and IL-6 have been isolated and the availability of recombinant proteins allowed the demonstration of the pleiotropic effects of these cytokines. IL-4, IL-5 and IL-6 bind to high affinity receptors (Kd = 1-6 x 10(-10) M) expressed in low numbers on cells. The IL-4R is expressed on virtually every cell type whereas the IL-6R and
J, Banchereau, J P, Galizzi
openaire   +1 more source

Interleukin-3 and Interleukin-4 in Childhood Brucellosis

Infection, 2002
The Th1/Th2 cytokine balance seems to be involved in the susceptibility or resistance to Brucella infection, however the precise role of interleukins in human brucellosis has not been thoroughly explored.The serum levels of interleukin-3 (IL-3) and interleukin-4 (IL-4) were measured by enzyme-linked immunosorbent assay (Quantikines, R&D Systems) in ...
Galanakis, E., Makis, A., Bourantas, K. L., Papadopoulou, Z. L.   +3 more
openaire   +3 more sources

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Role of interleukins in cancer

, 2012
Tato práce se zabývá interleukiny a je jich úlohou při nádorovém bujení. V první části je práce zaměřena na členění cytokinů, druhy jejich receptorů a nejčastější signalizační dráhy. V další části práce je stručně popsána imunologie nádorového bujení –
Nguyen, Thuy
core   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, EarlyView.
Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Arthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source